Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00995345 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone

A Phase 2 study, sponsored by ActivX Biosciences.

Completed
Registry status
Phase 2
Development phase
403
Enrollment target

NCT00995345: Completed Phase 2 study, sponsored by ActivX Biosciences.

NCT00995345 is a Phase 2 study that has completed, run by ActivX Biosciences. The registered enrollment target is 403 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (203% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00995345, a Phase 2 study, has completed, sponsored by ActivX Biosciences.

COMPLETED
Registry status
Phase 2
Development phase
403 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.

Primary Outcome

Mean Change in HbA1c (%) from Baseline to Week 24 with LOCF, ITT population LS mean (SE)

Interventions

  • DRUG Placebo
  • DRUG KRP-104

Trial Details

FieldValue
Enrollment Target 403 participants
Start Date 2009-10
Est. Completion 2011-01
Phase Phase 2
ActivX Biosciences

2 total trials

What the finished NCT00995345 record still lists

NCT00995345 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (203% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00995345 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00995345 about?

NCT00995345 is a clinical study titled "Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone". The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.

What is the current status of trial NCT00995345?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 403 participants. The study started on 2009-10. Estimated completion is 2011-01.

What interventions are being tested in trial NCT00995345?

The interventions under investigation include: Placebo (DRUG), KRP-104 (DRUG).

Who is sponsoring clinical trial NCT00995345?

This trial is sponsored by ActivX Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00995345's enrollment target sits among peer trials

403 96th of 2000 higher than 1,905 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05647122 · 403 participants · Phase 1

    First in Human Study of AZD9592 in Solid Tumors

  • NCT05674799 · 403 participants · NA

    NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

  • NCT06244771 · 403 participants · Phase 1

    A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • NCT05049057 · 404 participants · Phase 2

    Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00995345, the US trial registry maintained by the National Library of Medicine. NCT00995345 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.